Payment overview · 2025
General Payments
$595.60
36 reported records · 10 companies
Healthcare provider profile · identity verified
Anil Kumar Singh, M.D
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · EDISON, NJ · NPI 1023214897
Verified facts
What the public records show
CMS Open Payments records show Anil Kumar Singh, M.D received $595.60 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta, Veltassa.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Lokelma by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Veltassa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $179.89 | 30.2% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $131.04 | 22.0% | 8 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $81.09 | 13.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $54.19 | 9.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.19 | 8.1% | 3 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.57 | 5.3% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $19.13 | 3.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.91 | 3.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.50 | 2.8% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $16.09 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $595.60 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $131.04 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $111.98 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $94.13 | 6 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $81.09 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $67.91 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $54.19 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $30.30 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $30.30 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $30.30 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $16.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
| Veltassa veltassa |
2025 | Veltassa | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
34 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Veltassa open payments reported associated product |
CMS Open Payments — General Payments 5970 supporting records · 2480 recipient NPIs · example record 1172020739 |
Veltassa · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 527 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 381 | 96 |
| Metformin Hcl | Metformin Hcl | 309 | 86 |
| Losartan Potassium | Losartan Potassium | 293 | 75 |
| Furosemide | Furosemide | 227 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 159 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 61 |
| Gabapentin | Gabapentin | 150 | 36 |
| Azithromycin | Azithromycin | 143 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 31 |
| Carvedilol | Carvedilol | 114 | 33 |
| Alendronate Sodium | Alendronate Sodium | 107 | 30 |
| Januvia | Sitagliptin Phosphate | 92 | 21 |
| Lisinopril | Lisinopril | 89 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 20 |
| Prednisone | Prednisone | 77 | 52 |
| Potassium Chloride | Potassium Chloride | 73 | 21 |
| Meloxicam | Meloxicam | 70 | 30 |
| Clonidine Hcl | Clonidine Hcl | 67 | 18 |
| Famotidine | Famotidine | 67 | 24 |
| Enalapril Maleate | Enalapril Maleate | 66 | 14 |
| Omeprazole | Omeprazole | 66 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 57 | 16 |
| Simvastatin | Simvastatin | 57 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 56 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 52 | 23 |
| Montelukast Sodium | Montelukast Sodium | 51 | 16 |
| Glimepiride | Glimepiride | 50 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 15 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 47 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 12 |
| Donepezil Hcl | Donepezil Hcl | 42 | 13 |
| Metformin Hcl Er | Metformin Hcl | 42 | 14 |
| Allopurinol | Allopurinol | 41 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 16 |
| Eliquis | Apixaban | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | 11 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 31 |
| Lokelma | Sodium Zirconium Cyclosilicate | 34 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 33 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | 11 |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Lumigan | Bimatoprost | 19 | suppressed |
| Eplerenone | Eplerenone | 18 | suppressed |
| Klor-Con M10 | Potassium Chloride | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 12 |
| Trulicity | Dulaglutide | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 15 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | 12 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $595.60 · 36 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACCRUFER, BREZTRI, COMIRNATY, Cologuard Collection Kit, FARXIGA, Hillrom - Carnation Ambulatory Monitor, Kerendia, NURTEC ODT, OTEZLA, PAXLOVID, PREVNAR 20, REPATHA, TRELEGY ELLIPTA, Veltassa | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error